Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Consistent with the overall population, amivantamab-lazertinib significantly improved OS versus osimertinib among Asian participants with previously untreated EGFR-mutated advanced NSCLC, making it the first regimen to improve survival among Asian patients.
Authors
- Adlinda Alip (ORCID: https://orcid.org/0000-0003-4744-4533)
- Alianu K. Akawung (ORCID: https://orcid.org/0000-0002-4625-8563)
- E. Fennema
- Yuta Yamanaka (ORCID: https://orcid.org/0009-0009-7872-4395)
- James Chih-Hsin Yang
- Sujay Shah
- Hidetoshi Hayashi
- Koichi Azuma
- Gee-Chen Chang
- Hailin Xiong
- Seema Sethi
- Pongwut Danchaivijitr
- Byoung Chul Cho
- Xiaodan Tang
- Shun Lu
- Yu. Ya. Kim
- Se-Hoon Lee
- Kumar Prabhash
- Mehmet Ali Nahit Şendur
- Soon-Hin How
Institutions
- Kurume University (JP)
- Kansai Medical University (JP)
- Johnson & Johnson (United States) (US)
- Siriraj Hospital (TH)
- Yonsei University (KR)
- Tata Memorial Hospital (IN)
- Samsung Medical Center (KR)
- Shanghai Chest Hospital (CN)
- Seoul National University Bundang Hospital (KR)
- University of Malaya (MY)
- International Islamic University Malaysia (MY)
- Chung Shan Medical University Hospital (TW)
- Kindai University Sakai Hospital (JP)
- Johnson Electric (China) (CN)
- National Taiwan University Hospital (TW)
- Huizhou Central People's Hospital (CN)
- Ankara Yıldırım Beyazıt University (TR)
- Sungkyunkwan University (KR)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Lung Cancer
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1016/j.lungcan.2026.109305
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00